NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...

CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...

IMPACT STUDY The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study The Immune Profiling with Antibody-based COVID-19...

The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...

NCT04504825: Phase 3: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis...

(ITHACA) High-risk Smoldering Multiple Myeloma NCT04270409 NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and...

IFM 2017-04 - CARRISMM NCT04144387: Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New...

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy MGUS Rifaximin in Patients With Monoclonal Gammopathy This trial...

PROMISE NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population The PROMISE Study aims to...

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma This early phase I trial studies the side effects of...

NCT03657251: MMRF CureCloud Research Initiative NDMM RRMM MGUS/SMM MMRF CureCloud Research Initiative Observational Study The MMRF...

HO147SMM NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM...

ASCENT TRIAL Dara-KRd Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) This study evaluates the...

NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple...

NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...

Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) This study...

Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...

NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Trial of...

NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM A Study of PVX-410, a Cancer...

GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...

CENTAURUS A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma The purpose of this study...

NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma E-PRISM: Phase...

NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma KRd Multiple myeloma is a blood cancer...

ECOG E3A06 ECOG-ACRIN Cancer Research Group ECOG E3A06 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk...

QUIREDEX PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...